AFF1 and leukemia: Treatment of CRISPRKMT2A-AFF1 leukemia-engrafted mice (assessed by the presence of >1% leukemic cells in peripheral blood on day 6) with 5 × 106 bispecific CAR-iNKT cells resulted in 100% of CRISPRKMT2A-AFF1 leukemia-bearing mice surviving >60 days (Figure 3B-C) with no detectable HLA-class–positive cells in the BM or spleen, suggesting leukemia elimination (Figure 3D).